Methods of treating disorders associated with castor
US-2021023081-A1 · Jan 28, 2021 · US
Small molecule modulators of pantothenate kinases
US11891378B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11891378-B2 |
| Application number | US-201816958022-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 26, 2018 |
| Priority date | Dec 27, 2017 |
| Publication date | Feb 6, 2024 |
| Grant date | Feb 6, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure relates to chemical compounds that modulate pantothenate kinase (PanK) activity for the treatment of metabolic disorders (such as diabetes mellitus type II), neurologic disorders (such as pantothenate kinase-associated neurodegeneration), pharmaceutical compositions containing such compounds, and their use in treatment. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound, represented by the formula: or a pharmaceutically acceptable salt thereof. 2. A pharmaceutical composition, comprising a compound, represented by the formula: or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. 3. The pharmaceutical composition of claim 2 , in an oral dosage form.
Assignees
Inventors
Classifications
- C07D403/04Primary
directly linked by a ring-member-to-ring-member bond · CPC title
the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid (carnitine A61K31/205) · CPC title
- C07D237/24Primary
Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen · CPC title
Nitrogen atoms (nitro radicals C07D237/12) · CPC title
for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11891378B2 cover?
- The present disclosure relates to chemical compounds that modulate pantothenate kinase (PanK) activity for the treatment of metabolic disorders (such as diabetes mellitus type II), neurologic disorders (such as pantothenate kinase-associated neurodegeneration), pharmaceutical compositions containing such compounds, and their use in treatment. This abstract is intended as a scanning tool for pur…
- Who is the assignee on this patent?
- St Jude Childrens Res Hospital Inc, Coa Therapeutics Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D403/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Feb 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 6 related publications on this page (citations in our corpus or others sharing the same primary CPC).